mTORC2 phosphorylation of Akt1: A possible mechanism for hydrogen sulfide-induced cardioprotection

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Zhou, Yue ^a   Wang, Daying ^b   Gao, Xiufang ^c   Lew, Karsheng ^a   Richards, Arthur Mark ^a   Wang, Peipei ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Putuo Hospital   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; HYDROGEN SULFIDE; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN BCL 2; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, RAT; CARDIOTONIC AGENT; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PTEN PROTEIN, RAT; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR RESPONSE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME RELEASE; HEART FUNCTION; HEART PROTECTION; HEART WORK; MALE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; REOXYGENATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; METABOLISM; MUSCLE CELL; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; REPERFUSION INJURY;

ANIMALS; CARDIOTONIC AGENTS; CHROMONES; HUMANS; HYDROGEN SULFIDE; MORPHOLINES; MULTIPROTEIN COMPLEXES; MUSCLE CELLS; ORGAN CULTURE TECHNIQUES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RATS; REPERFUSION INJURY; TOR SERINE-THREONINE KINASES;

EID: 84903289113     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099665     Document Type: Article

References (46)

1. Abe K, Kimura H (1996) The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071. (Pubitemid 26140863)
2. Chen L, Ingrid S, Ding YG, Liu Y, Qi JG, et al. (2007) Imbalance of endogenous homocysteine and hydrogen sulfide metabolic pathway in essential hypertensive children. Chin Med J (Engl) 120: 389-393. (Pubitemid 46488350)
3. Geng B, Chang L, Pan C, Qi Y, Zhao J, et al. (2004) Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun 318: 756-763. (Pubitemid 38624219)
4. Sen U, Vacek TP, Hughes WM, Kumar M, Moshal KS, et al. (2008) Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology 82: 201-213.
5. Yang G, Wu L, Jiang B, Yang W, Qi J, et al. (2008) H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587-590.
6. Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, et al. (2006) Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther 316: 670-678. (Pubitemid 43130994)
7. Yong QC, Lee SW, Foo CS, Neo KL, Chen X, et al. (2008) Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol 295: H1330-H1340.
8. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, et al. (2007) Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 104: 15560-15565. (Pubitemid 47502956)
9. Osipov RM, Robich MP, Feng J, Liu Y, Clements RT, et al. (2009) Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection. J Cardiovasc Pharmacol 54: 287-297.
10. Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, et al. (2009) Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/ reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 120: S31-36.
11. Bliksoen M, Kaljusto ML, Vaage J, Stenslokken KO (2008) Effects of hydrogen sulphide on ischaemia-reperfusion injury and ischaemic preconditioning in the isolated, perfused rat heart. Eur J Cardiothorac Surg 34: 344-349.
12. Hu Y, Chen X, Pan TT, Neo KL, Lee SW, et al. (2008) Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch 455: 607-616. (Pubitemid 350160475)
13. Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448-460. (Pubitemid 38210151)
14. Matsui T, Li L, del Monte F, Fukui Y, Franke TF, et al. (1999) Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 2373-2379.
15. Pan LL, Liu XH, Gong QH, Zhu YZ (2011) S-Propargyl-cysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfide-dependent mechanism. Amino Acids 41: 205- 215.
16. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, et al. (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404: 15-21. (Pubitemid 46788080)
17. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1- yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem 282: 24463-24470. (Pubitemid 47328068)
18. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3- kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619. (Pubitemid 44100518)
19. Hwang SK, Kim HH (2011) The functions of mTOR in ischemic diseases. BMB Rep 44: 506-511.
20. Bar N, Dikstein R (2010) miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 5: e10859.
21. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, et al. (2010) MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70: 2339-2349.
22. Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917-931. (Pubitemid 46436532)
23. Chung EJ, Moon SW, Jung SA, Cho YJ, Kim SW, et al. (2010) Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway. Invest Ophthalmol Vis Sci 51: 6232-6237.
24. Das S, Cordis GA, Maulik N, Das DK (2005) Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol 288: H328-335. (Pubitemid 40023863)
25. Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, et al. (2003) Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol 284: H2351-2359. (Pubitemid 36622451)
26. Whiteman M, Moore PK (2009) Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med 13: 488-507.
27. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, et al. (2007) A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 321: 213-220. (Pubitemid 46456960)
28. Wang P, Tate JM, Lloyd SG (2008) Low carbohydrate diet decreases myocardial insulin signaling and increases susceptibility to myocardial ischemia. Life Sci 83: 836-844.
29. Wang P, Lloyd SG, Chatham JC (2005) Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart. Circulation 111: 2066-2072. (Pubitemid 40577901)
30. Aoyagi T, Kusakari Y, Xiao CY, Inouye BT, Takahashi M, et al. (2012) Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 303: H75-85.
31. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128. (Pubitemid 39468014)
32. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
34. Walsh K (2006) Akt signaling and growth of the heart. Circulation 113: 2032- 2034.
35. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, et al. (2003) Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112: 197-208. (Pubitemid 38056356)
36. Franke TF, Kaplan DR, Cantley LC, Toker A (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668. (Pubitemid 27061333)
37. Persad S, Attwell S, Gray V, Mawji N, Deng JT, et al. (2001) Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276: 27462-27469.
38. Degrande ST, Little S, Nixon DJ, Wright P, Snyder J, et al. (2012) Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart. J Biol Chem.
39. Volkers M, Konstandin MH, Doroudgar S, Toko H, Quijada P, et al. (2013) mTORC2 Protects the Heart from Ischemic Damage. Circulation.
40. Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK, et al. (2010) Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 86: 103-112.
41. Kelly PN, Strasser A (2011) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18: 1414-1424.
42. Hsu YT, Wolter KG, Youle RJ (1997) Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A 94: 3668-3672.
43. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ (2004) Survival factorinduced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A 101: 15313-15317. (Pubitemid 39441538)
44. Meller R (2009) The role of the ubiquitin proteasome system in ischemia and ischemic tolerance. Neuroscientist 15: 243-260.
45. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P (2001) Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276: 2571-2575.
46. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, et al. (1998) Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A 95: 14681-14686. (Pubitemid 29003690)